-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Moderna to Present at Upcoming Conference in November 2026
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Silicon Publishing Launches Prism, Bringing AI-Assisted Automation to Database Publishing
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
NextBoat Inc. to Announce Third Quarter 2026 Financial and Operating Results on Monday, November 16, 2026
-
Retired Army Officer Earns Two Degrees While Navigating Family Health Challenges
-
Remergify Opens Waitlist for AI Allowance, a Plain-English Way to Let AI Assistants Shop Within Limits You Set
-
An Investigational Drug to Tackle Measles Outbreaks
-
Ondas Receives Purchase Order for Next-Generation Tactical Attack Drones, Aims to Leverage Planned ARAN Defense Acquisition to Manufacture Thousands of Systems
-
First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
-
Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
-
ACCESS Newswire Reports Third Quarter 2026 Results
-
T4 Robotics Appoints Paul Hughes as Co-CEO and Announces Expansion into Unmanned Maritime Systems
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
VANCOUVER, BC / ACCESS Newswire / May 16, 2025 / Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol "ONCO", and the Company has submitted a request to voluntarily delist its Common Shares from the CSE, which is expected to take effect at the close of trading on May 21, 2025. No action is required from shareholders regarding this transition.
Cboe Canada, a Tier 1 stock exchange and part of the global Cboe Markets network, offers a robust and internationally recognized platform for innovative companies seeking investor trust, liquidity, and visibility. Since launching in 2015, Cboe Canada has supported issuers through advanced market infrastructure and access to real-time data solutions, including its ETF Market Canada platform - an institutional-grade resource for exploring and analyzing over 1,200 Canadian ETFs. Real-time quotes and market information on Onco-Innovations can be found at www.cboe.com.
"Our move to Cboe Canada is a pivotal step in Onco-Innovations' journey as we scale our operations and deepen our commitment to developing impactful oncology solutions. This listing will not only enhance our visibility within the capital markets but also place us alongside a growing roster of forward-thinking companies focused on long-term value creation. We see this as an opportunity to broaden our investor base, strengthen engagement with institutions, and ensure that our capital strategy evolves in step with our scientific ambitions," stated Thomas O'Shaughnessy, CEO of the Company.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
Thomas O'Shaughnessy
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
The CSE and Cboe Canada have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the commencement of trading of the Common Shares on Cboe Canada, the Company's request to voluntarily delist the Common Shares from the CSE, and the Company's future goals and objectives. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain acts, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved".
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to transferring the Company's listing of its Common Shares from the CSE to Cboe Canada, the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all. Accordingly, readers should not place undue reliance on any such forward-looking information.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
P.Santos--AMWN